TriangleCyclophosphamide (NCT04216524)
Cyclophosphamide trial for Blastic Plasmacytoid Dendritic Cell Neoplasm (NCT04216524). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed, relapsed or refractory blastic plasmacytoid dendritic cell neoplasm. Limited prior emergency treatment is allowed.
The idea: tagraxofusp carries a toxin to IL-3 receptors; venetoclax blocks the survival protein BCL-2. Treatment starts with intravenous tagraxofusp, then combines it with oral venetoclax and alternating chemotherapy. Chemotherapy intensity changes at age 60. Transplant is possible for some patients; others continue treatment. Researchers assess progression, responses and safety.
This phase 2 study plans 40 patients. Naveen Pemmaraju leads it at MD Anderson in Houston, the single recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.